Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
spacer
Blue curve MMWR spacer
spacer
spacer

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Notice to Readers: Update: Supply of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine

Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) remains in short supply, and the shortage will continue into mid-2002 (1). Shortages are greatest in the public sector. Despite high vaccination rates, pertussis continues to cause serious illness and death, particularly among infants aged <6 months who are too young to have completed the 3-dose primary series of DTaP. In 2000, a total of 1,873 pertussis cases (rate: 99 per 100,000 infants aged <6 months) and 16 deaths were reported among infants aged <6 months. Vaccinating infants on time with the 3-dose primary series of DTaP to protect them from serious disease remains a priority during this vaccine shortage.

The shortage began in 2000 when two manufacturers (Wyeth Lederle, Pearl River, New York, and Baxter Hyland Immuno Vaccines, Baltimore, Maryland) stopped production of DTaP (1). Aventis Pasteur (Swiftwater, Pennsylvania) and GlaxoSmithKline (Philadelphia, Pennsylvania), producers of Tripedia® and Infanrix, respectively, are the only two U.S. suppliers.

DTaP is recommended as a 5-dose series: 3 doses administered to infants at ages 2, 4, and 6 months, followed by 2 additional doses at age 15--18 months and at age 4--6 years (2). During the shortage of DTaP, the Advisory Committee on Immunization Practices recommends that providers who do not have enough DTaP to vaccinate all children with 5 doses give priority to vaccinating infants with the first 3 doses. To ensure an adequate supply of DTaP to vaccinate infants, providers should first defer vaccination of children aged 15--18 months with the fourth DTaP dose. If deferring the fourth dose does not leave enough DTaP to vaccinate infants, then the fifth DTaP dose (given to children aged 4--6 years) also should be deferred*. In areas with severe DTaP shortages, local public health officials might elect to recommend communitywide deferral of the fourth DTaP dose, and, if necessary, the fifth DTaP dose.

When the DTaP shortage ends, providers should recall and administer DTaP to all children who missed a dose. Vaccination of children aged 4--6 years is needed to ensure immunity to pertussis, diphtheria, and tetanus during the elementary school years (2).

References

  1. CDC. Update on the supply of tetanus and diphtheria toxoids and of tetanus and diphtheria toxoids and acellular pertussis vaccine. MMWR 2001;50:189--90.
  2. CDC. Pertussis vaccination: use of acellular pertussis vaccine among infants and young children---recommendations of the Advisory Committee on Immunization Practices. MMWR 1997;46(no. RR-7).
  3. CDC. Recommended childhood immunization schedule---United States, 2001. MMWR 2001;50:7--10,19.

*Children traveling to countries where the risk for diphtheria is high should be vaccinated according to the Recommended Childhood Immunization Schedule (3). Travelers might be at increased risk for exposure to toxigenic strains of Corynebacterium diphtheriae, especially with prolonged travel, extensive contact with children, or exposure to poor hygiene. High-risk countries include Africa---Algeria, Egypt, and sub-Saharan Africa; Americas---Brazil, Dominican Republic, Ecuador, and Haiti; Asia/Oceania---Afghanistan, Bangladesh, Cambodia, China, India, Indonesia, Iran, Iraq, Laos, Mongolia, Myanmar, Nepal, Pakistan, Philippines, Syria, Thailand, Turkey, Vietnam, and Yemen; and Europe---Albania and all countries of the former Soviet Union.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

Disclaimer   All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Page converted: 1/3/2002

HOME  |  ABOUT MMWR  |  MMWR SEARCH  |  DOWNLOADS  |  RSSCONTACT
POLICY  |  DISCLAIMER  |  ACCESSIBILITY

Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A

USA.GovDHHS

Department of Health
and Human Services

This page last reviewed 1/3/2002